Cargando…

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score

BACKGROUND: The development of molecular techniques to estimate the risk of breast cancer recurrence has been a significant addition to the suite of tools available to pathologists and breast oncologists. It has previously been shown that immunohistochemistry can provide a surrogate measure of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarella, Mark D., Heintzelman, Rebecca C., Popnikolov, Nikolay K., Garcia, Fernando U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299556/ https://www.ncbi.nlm.nih.gov/pubmed/30574014 http://dx.doi.org/10.1186/s12907-018-0082-3

Ejemplares similares

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score(®) Test in Node-Negative Early Breast Cancer
por: Berdunov, Vladislav, et al.
Publicado: (2022)

Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer
por: Lee, Lik Hang, et al.
Publicado: (2017)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2023)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
por: Kim, Jae-Myung, et al.
Publicado: (2018)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

Breast Cancer with Low Recurrence Score on Oncotype DX(©): Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
por: Zarbiv, Yonaton, et al.
Publicado: (2022)

A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed
por: Ceccarelli, Claudio, et al.
Publicado: (2019)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
por: Emmadi, Rajyasree, et al.
Publicado: (2015)

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
por: Orucevic, Amila, et al.
Publicado: (2017)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
por: Aherne, T. M., et al.
Publicado: (2020)

Impact of Oncotype DX Recurrence Score on the Patterns of Locoregional Recurrence in Breast Cancer (Korean Radiation Oncology Group 19-06)
por: Kim, Kyubo, et al.
Publicado: (2020)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer
por: Layman, Rachel M., et al.
Publicado: (2022)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
por: Fried, Georgeta, et al.
Publicado: (2014)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
por: Li, Hongxiao, et al.
Publicado: (2022)

Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
por: Kerin, Eoin P., et al.
Publicado: (2022)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
por: Klein, Molly E, et al.
Publicado: (2013)

Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
por: Ozmen, Vahit, et al.
Publicado: (2016)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
por: Cohen, Pascale A., et al.
Publicado: (2019)

Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT(2)-Profiler Multiplex RT-PCR
por: Schildgen, Verena, et al.
Publicado: (2019)

Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
por: Chen, Rui, et al.
Publicado: (2021)

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
por: Malo, Teri L., et al.
Publicado: (2012)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
por: Zhang, Michelle, et al.
Publicado: (2021)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
por: Zhu, Xiaofu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pp4mn0r9b1huq5aao5ev118sbe